3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Neoplasm Metastasis
5
Colorectal Neoplasms
4
Solid Tumor
3
Stomach Neoplasms
2
Melanoma
2
Endometrial Neoplasms
2
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Rectal Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms
1
Metastatic Solid Tumors
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma
1
Extensive Stage Small Cell Lung Cancer
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms, Hereditary Nonpolyposis
1
Colonic Neoplasms
1
Breast Neoplasms
1
Advanced Solid Tumors
1
Adenocarcinoma
1
Interventions
Lenalidomide
5
Rituximab
4
Brentuximab Vedotin
4
Vincristine
3
Etoposide
3
Cyclophosphamide
3
romidepsin
2
Vorinostat
2
Granulocyte Colony-Stimulating Factor
2
Gemcitabine
2
Doxorubicin
2
Dasatinib
2
tislelizumab
1
selinexor
1
plerixafor
1
pembrolizumab
1
pegfilgrastim
1
parsaclisib
1
obinutuzumab
1
obatoclax
1
monomethyl auristatin E
1
liposomal doxorubicin
1
ixazomib
1
idelalisib
1
ibrutinib
1
gemcitabine-oxaliplatin regimen
1
fludarabine
1
etoposide phosphate
1
denileukin diftitox
1
copanlisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Lymphoma, T-Cell, Peripheral
×
tislelizumab
×
Clear all
NCT04425070
2026-01-05
TOUCH
Antengene Corporation
Phase 1/2
Terminated
56 enrolled